Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast
 

Bionovo, Inc. (NASDAQ:BNVI) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia.

More...